---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266867"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:19:21.458867+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26

## Summary
- Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.
- Phase 2 MaGic trial of claseprubart in gMG met endpoints with stat sig MG-ADL and QMG improvements at Week 13.
- CIDP Phase 3 CAPTIVATE trial interim responder analysis accelerated to Q2'26 (from 2H'26) due to faster enrollment.
- In-licensed DNTH212 (bifunctional BDCA2/BAFF-APRIL inhibitor) from Leads Biolabs; Ph1 healthy volunteer data expected 2H'26.
- Adjusted cash ~$525M after $30M DNTH212 milestone payments; runway into 2028.

## SEC filing metadata
- accession: 0001193125-25-266867
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312525266867/0001193125-25-266867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312525266867/dnth-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266867
- JSON: https://secwatch.observer/filing/0001193125-25-266867.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.